Deficiency of complement decay-accelerating factor (DAF, CD55) in non-Hodgkin's lymphoma

Area of Science:

• Immunology
• Hematology
• Complement System Biology

Background:

• Complement regulatory proteins, decay-accelerating factor (DAF) and membrane cofactor protein (MCP), are crucial for preventing self-attack by the complement system.
• Dysregulation of these proteins is implicated in various hematological malignancies.
• Previous studies have not extensively characterized DAF and MCP expression in diverse hematological cancers.

Purpose of the Study:

• To investigate the expression levels of DAF and MCP on malignant cells from patients with hematological malignancies.
• To determine if DAF deficiency is a specific characteristic of certain hematological cancers, particularly non-Hodgkin's lymphoma (NHL).
• To explore the therapeutic potential of targeting MCP in DAF-deficient NHL cells.

Main Methods:

• Flow cytometry was used to assess surface expression of DAF and MCP on cells from patients with various hematological malignancies.
• Patients included those with non-Hodgkin's lymphoma (NHL), acute non-lymphocytic leukemia (ANLL), chronic myelogenous leukemia (CML), acute lymphocytic leukemia (ALL), and chronic lymphocytic leukemia (CLL).
• DAF-negative NHL cells were treated with an anti-MCP antibody (M177) followed by serum to assess complement C3 deposition.

Main Results:

• All malignant and non-malignant blood cells expressed MCP.
• Complete deficiency of DAF was observed in 2 out of 10 patients with non-Hodgkin's lymphoma (NHL).
• None of the patients with ANLL, CML, ALL, or CLL showed DAF deficiency. The two DAF-negative NHL cases were distinct from paroxysmal nocturnal hemoglobinuria (PNH) and showed both T and B cell markers. Treatment with anti-MCP antibody (M177) induced efficient homologous C3 deposition on these DAF-negative NHL cells.

Conclusions:

• A subset of non-Hodgkin's lymphoma (NHL) specifically lacks decay-accelerating factor (DAF) expression on malignant cells.
• This DAF deficiency in NHL cells can be overcome by targeting membrane cofactor protein (MCP) with antibody M177, leading to complement-mediated cell damage.
• These findings suggest that targeting MCP could be a viable therapeutic strategy for DAF-deficient NHL.